It has been observed both in Europe and in the USA that there is an underuse of surgery in patients with MR when indicated. This occurs with the frequent finding that risk evaluation is not adequate, leading to undertreatment of the sickest patients while conversely lower risk patients are often overtreated. [4] [5] [6] [7] The search for an improvement of risk stratification in patients with degenerative MR was the aim of the study published by Grigioni et al. in this issue of the journal. 8 The goal was to define a score to predict early and late mortality. The authors should be congratulated for putting together what is the largest study ever published on degenerative MR since it included >3000 patients. The patient population comes from two registries: the MIDA Flail registry (2472 patients) was used as a derivation cohort for the score, and the MIDA BNP registry (1194 patients) served as the validation cohort. Besides its size, one of the strengths of the study is that it included patients from several countries, suggesting a good representation of the presentation of patients with degenerative MR and practices worldwide. Among the potential limitations of the present study we should take into account the fact that the inclusion period covers more than two decades, which may lead to significant changes in practices as regards both diagnosis and management. Although no specific information was given about co-morbidities, the patient population seems to be at relatively low risk since EuroSCORE II ranged from 1 to a maximum of 2.48, mean age was 66 years, a large proportion of patients were asymptomatic, and mean left ventricular ejection fraction was 64%. Thus it is likely that the high-risk patients currently treated using percutaneous device are under-represented here. We also lack precision as regards the methods used for grading the severity of MR; however, it was assessed using an integrative approach in experienced teams. In addition, most patients had flail leaflets which usually results in severe MR.
The MIDA score was derived from the derivation cohort by weighing clinical and echocardiographic parameters which are in the guidelines: age > _65 years, left atrium diameter > _55 mm, left ventricular ejection fraction > _60%, left ventricular end-diastolic diameter > _40 mm, heart failure symptoms, atrial fibrillation, and right ventricular systolic pressure > _50 mmHg. All criteria corresponding to recommendations for surgery in guidelines were strongly associated with outcome, and this is a further proof of the validity of guidelines and of the relevance of the proposed thresholds. 9, 10 The positive aspects of this score are that it includes both clinical and echo variables taking into account all criteria together with a weight which is proportional to their prognostic impact. The MIDA score is simple, thus it may be expected to be user-friendly which may facilitate its use in practice. The score showed a good discrimination and also a good calibration, with a C index of 0.78 and 0.81, respectively. Finally it appears that the MIDA score adds incremental value in comparison with the guideline-provided prognostic markers and the EuroSCORE II for predicting 1-and 5-year mortality. The fact that the MIDA score has a good predictive performance of 1-year mortality in medically treated patients is an important contribution in decision-making since it allows for a better assessment of the respective outcomes of operated and medically treated patients. The predictive value of the MIDA score in operated patients further highlights the prognostic impact of the consequences of MR on the left ventricle, left atrium, and pulmonary pressures. This is a further A number of methodological limitations do, however, exist, among which one of the most important is the fact that the populations in the derivation and validation cohorts were significantly different as regards important characteristics such as gender (males: 72% in the derivation cohort vs. 65% in the validation cohort), symptoms (asymptomatic patients: 67% vs. 43%), and number of patients with flail leaflets (96% vs. 77%).
It is understandable that performing such a large study was at the price of some heterogeneity and it would be theoretically desirable to concentrate on a more homogenous population with flail leaflets only, severe MR assessed using precise quantification methods, and including only asymptomatic patients where decision-making is more difficult, while surgery is theoretically indicated when MR is severe and symptoms are present. Finally, percutaneous treatment should be part of the treatment performed since it has a growing role in current practice when affordable.
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Beyond the issues intrinsic to the value of this score, it is a bit of an oversimplification to think that a score can summarize all the factors in the decision, even more so when addressing a population of elderly patients with a large number of co-morbidities, which are not taken into account in the MIDA score. A simple score could be used more often but it will not provide the solution for the management of a specific patient. 12, 13 In such cases, the only way to proceed is the judgement of a Heart Team integrating a number of clinical, anatomic, and procedural variables. Such a process was recently put forward and is now recommended in the new ESC EACTS guidelines on the management of valvular disease. 14 The suggestion that undertreatment is largely due to the absence of such a score also somewhat oversimplifies the problem because the reasons are probably multiple. In the MIDA registry, patients who were denied surgery were at higher operative risk, as shown by differences in risk scores. This finding was the same in the Euro Heart Survey, in which the EuroSCORE was higher in patients referred to surgery than in those medically treated, although all of them had a theoretical indication for surgery. 4, 5 We share the opinion of the authors that this finding suggests that the operative risk is overstressed in decision-making. High-risk patients are also likely to have a particularly poor outcome under medical therapy, but this does not seem to be fully taken into account by the practitioners in charge of the therapeutic decision. A process needs to be followed to overcome undertreatment of MR. The first step would be to identify gaps in knowledge. This can be done by awareness studies performed among primary care physicians and cardiologists. 15 A similar effort was made in Europe and was presented during the last annual congress. In parallel, another way to identify the gaps in knowledge will come from registries such as the Euro Heart Survey and its second phase which was just finalized and included >7000 patients throughout Europe, the results of which are to be expected next year. This identification of the gaps will facilitate the development of new educational programmes specifically targeting the gaps derived from awareness studies and registries. The efficacy of educational programmes will then be evaluated based on changes in knowledge and, more importantly, practices and outcomes to be evaluated by repeated registries. Thus this study contributes to an improvement in our knowledge in the management of degenerative MR, but there is still a lot of work to be done.
